Here, we have analyzed the therapeutic potential for the novel, orally available dual PI3K/mTOR inhibitor NVP-BEZ235, which has entered clinical trials with low side-effects of solid tumors, including colon cancer. The gene discussed is MTOR; the disease is malignant colon neoplasm.